2021 General Assembly and Cardiology seminar

General Assembly 2021

Save the date for the next BELNUC General Assembly and Cardiology seminar on “Cardiac Amyloidosis: A Tantalizing Topic Reimagined (ATTR)”, to be held as a virtual meeting on Saturday, March 6th 2021. Registration deadline March 1st 2021.

This seminar targets physicians that are involved in the diagnosis and treatment of ATTR, including nuclear medicine physicians and cardiologists. The presentations will familiarize the attendees with the clinical features of cardiac ATTR amyloidosis and describe the diagnostic tests to determine ATTR type. A correct diagnosis is ever more crucial, given that several novel therapies for ATTR amyloidosis have become available. Download the flyer here.

Cardiac Amyloidosis: A Tantalizing Topic Reimagined (ATTR)

  • RIZIV/INAMI accreditation 3 CP approved (N° 20022019; category: 3)1
  • FANC/AFCN radiation protection continuing education: 1.0 hour for nuclear medicine physicians
  • Venue: Virtual only

Start your registration here!

1 RIZIV/INAMI accreditation for nuclear medicine physicians is available for BELNUC members only.

With financial support from Pfizer.


Programme

Moderators: Dr. Jeroen Mertens (AZ Maria Middelares, Ghent)

09:00 – 09:45 General assembly
BELNUC Board
09:45 – 10:00 Break
10:00 – 10:30 Clinical aspects of cardiac amyloidosis
Prof. dr. Steven Droogmans (UZ Brussels)
10:30 – 11:00 Diagnosis of cardiac amyloidosis
Prof. dr. Olivier Gheysens (UC Louvain)
11:00 – 11:15 Break
11:15 – 11:30 Organizing multi-disciplinary care in cardiac amyloidosis
Prof. dr. Steven Droogmans (UZ Brussels) and Prof. dr. Olivier Gheysens (UC Louvain)
11:30 – 12:00 Case presentation
Moderator: Dr. Jeroen Mertens (AZ Maria Middelares, Ghent)

Panelists: Prof. dr. Steven Droogmans (UZ Brussels) and Prof. dr. Olivier Gheysens (UC Louvain)

12:00 – 12:30 Q&A

 


Selminar Cardiac Transthyretin Amyloidosis

Cardiac amyloidosis of transthyretin fibril protein (ATTR) type is an infiltrative cardiomyopathy characterized by ventricular wall thickening and diastolic heart failure. Improved awareness and advances in diagnosis have led to a marked increase in patients with wild-type ATTR (senile systemic) amyloidosis and Afro-Caribbean patients with the hereditary ATTR V122I type. Both subtypes present predominantly as isolated cardiomyopathy. The differential diagnosis includes cardiac amyloid light-chain (AL) amyloidosis, which has a poorer prognosis and can be amenable to chemotherapy. This seminar targets physicians that are involved in the diagnosis and treatment of ATTR, including nuclear medicine physicians and cardiologists. The presentations will familiarize the attendees with the clinical features of cardiac ATTR amyloidosis and describe the diagnostic tests to determine ATTR type. A correct diagnosis is ever more crucial, given that several novel therapies for ATTR amyloidosis have become available.

1) Refresh the epidemiology and pathophysiology of cardiac amyloidosis with a focus on ATTR.

2) Present the clinical manifestations and treatment options for ATTR.

3) Discuss the diagnosis of ATTR, with a focus on the use of radionuclide imaging.

4) Present best-practice examples of establishing a multidisciplinary care pathway for ATTR patients

5) Engage interactive discussion using case examples

The recent introduction of effective therapies for ATTR has led to increased importance in the correct diagnosis of this condition. There is currently a need for imaging specialists to become aware of this condition and how to appropriately perform and interpret the diagnostic imaging studies. Moreover, there is a need for improved collaboration between clinical and imaging specialists in order not to miss patients with ATTR.